Venn completes acquisition of Kinesis

Venn Life Sciences (AIM: VENN), a growing Clinical Research Organisation providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces the completion of the acquisition of Kinesis Pharma BV.

Tony Richardson, Chief Executive Officer of Venn said: “We are pleased that the acquisition of Kinesis Pharma BV has completed as it has established Venn as a highly differentiated European Contract Research Organisation and is in line with Company’s strategy. We look forward to offering the complete range of services to our clients allowing us to establish earlier and longer lasting client relationships. We look forward to seeing the benefits of this acquisition in the near future.”

Important information

This information is of a general nature and does not constitute an offer to provide services.

The opinions and conclusions given here are those of Seneca Partners and are subject to change without notice.

The value of investments and/or any income arising from them may fluctuate.

Past performance is not necessarily a guide to future performance.

Important notice

The products and services shown on this website place capital at risk. Investors may receive less in returns than they have invested. Investments may not allow for capital to be withdrawn on demand. If an investment provides tax relief then this relief is subject to change and is dependant on personal circumstances. Any reference to past performance or forecasted performance is not a reliable indicator of future performance.

Seneca Partners recommends that any investor seeks specialised financial and/or tax advice before investing. Seneca Partners does not provide advice and the information on this website, including but not limited to news, should not be construed as such.

Please confirm that you understand this warning and wish to proceed.